GENMAB A/S -SP ADR (GMAB) Stock Fundamental Analysis
NASDAQ:GMAB - Nasdaq - US3723032062 - ADR - Currency: USD
We assign a fundamental rating of 7 out of 10 to GMAB. GMAB was compared to 571 industry peers in the Biotechnology industry. GMAB scores excellent points on both the profitability and health parts. This is a solid base for a good stock. GMAB has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make GMAB a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
GMAB had positive earnings in the past year.
In the past year GMAB had a positive cash flow from operations.
In the past 5 years GMAB has always been profitable.
GMAB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 17.12%, GMAB belongs to the best of the industry, outperforming 97.50% of the companies in the same industry.
GMAB has a better Return On Equity (21.38%) than 97.14% of its industry peers.
GMAB's Return On Invested Capital of 13.92% is amongst the best of the industry. GMAB outperforms 96.96% of its industry peers.
GMAB had an Average Return On Invested Capital over the past 3 years of 15.19%. This is in line with the industry average of 14.39%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.12% | ||
| ROE | 21.38% | ||
| ROIC | 13.92% |
ROA(3y)15.85%
ROA(5y)16.41%
ROE(3y)18.38%
ROE(5y)18.67%
ROIC(3y)15.19%
ROIC(5y)16.37%
1.3 Margins
GMAB's Profit Margin of 36.44% is amongst the best of the industry. GMAB outperforms 98.39% of its industry peers.
GMAB's Profit Margin has declined in the last couple of years.
GMAB has a better Operating Margin (32.18%) than 98.75% of its industry peers.
In the last couple of years the Operating Margin of GMAB has declined.
GMAB's Gross Margin of 95.42% is amongst the best of the industry. GMAB outperforms 95.54% of its industry peers.
GMAB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.18% | ||
| PM (TTM) | 36.44% | ||
| GM | 95.42% |
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
GMAB has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, GMAB has less shares outstanding
The number of shares outstanding for GMAB has been reduced compared to 5 years ago.
GMAB has a worse debt/assets ratio than last year.
2.2 Solvency
GMAB has an Altman-Z score of 9.12. This indicates that GMAB is financially healthy and has little risk of bankruptcy at the moment.
GMAB's Altman-Z score of 9.12 is amongst the best of the industry. GMAB outperforms 87.68% of its industry peers.
GMAB has a debt to FCF ratio of 0.14. This is a very positive value and a sign of high solvency as it would only need 0.14 years to pay back of all of its debts.
GMAB has a Debt to FCF ratio of 0.14. This is amongst the best in the industry. GMAB outperforms 96.96% of its industry peers.
GMAB has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.03, GMAB perfoms like the industry average, outperforming 40.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 0.14 | ||
| Altman-Z | 9.12 |
ROIC/WACC2.04
WACC6.82%
2.3 Liquidity
A Current Ratio of 5.25 indicates that GMAB has no problem at all paying its short term obligations.
GMAB has a Current ratio (5.25) which is in line with its industry peers.
A Quick Ratio of 5.24 indicates that GMAB has no problem at all paying its short term obligations.
GMAB has a Quick ratio (5.24) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.25 | ||
| Quick Ratio | 5.24 |
3. Growth
3.1 Past
The earnings per share for GMAB have decreased by -0.37% in the last year.
Measured over the past years, GMAB shows a quite strong growth in Earnings Per Share. The EPS has been growing by 14.25% on average per year.
GMAB shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.67%.
GMAB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 32.03% yearly.
EPS 1Y (TTM)-0.37%
EPS 3Y13.04%
EPS 5Y14.25%
EPS Q2Q%-57.68%
Revenue 1Y (TTM)30.67%
Revenue growth 3Y36.75%
Revenue growth 5Y32.03%
Sales Q2Q%41.39%
3.2 Future
The Earnings Per Share is expected to grow by 22.52% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 13.17% on average over the next years. This is quite good.
EPS Next Y55.36%
EPS Next 2Y38.79%
EPS Next 3Y36.51%
EPS Next 5Y22.52%
Revenue Next Year17.69%
Revenue Next 2Y16.08%
Revenue Next 3Y19.84%
Revenue Next 5Y13.17%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 25.05, the valuation of GMAB can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 95.54% of the companies listed in the same industry.
GMAB is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 29.75, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 16.09, which indicates a correct valuation of GMAB.
GMAB's Price/Forward Earnings ratio is rather cheap when compared to the industry. GMAB is cheaper than 95.36% of the companies in the same industry.
GMAB's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.05 | ||
| Fwd PE | 16.09 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, GMAB is valued cheaply inside the industry as 97.68% of the companies are valued more expensively.
97.14% of the companies in the same industry are more expensive than GMAB, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.13 | ||
| EV/EBITDA | 9.9 |
4.3 Compensation for Growth
GMAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
GMAB has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as GMAB's earnings are expected to grow with 36.51% in the coming years.
PEG (NY)0.45
PEG (5Y)1.76
EPS Next 2Y38.79%
EPS Next 3Y36.51%
5. Dividend
5.1 Amount
No dividends for GMAB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:GMAB (3/4/2025, 12:51:03 PM)
23.3
+0.34 (+1.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners40.98%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap14.80B
Analysts75.33
Price Target129.74 (456.82%)
Short Float %0.27%
Short Ratio1.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-47.78%
Min EPS beat(2)-84.28%
Max EPS beat(2)-11.29%
EPS beat(4)2
Avg EPS beat(4)-6.22%
Min EPS beat(4)-84.28%
Max EPS beat(4)67.24%
EPS beat(8)4
Avg EPS beat(8)-7.85%
EPS beat(12)7
Avg EPS beat(12)8.46%
EPS beat(16)10
Avg EPS beat(16)30.7%
Revenue beat(2)1
Avg Revenue beat(2)-1.55%
Min Revenue beat(2)-4.27%
Max Revenue beat(2)1.17%
Revenue beat(4)3
Avg Revenue beat(4)1.9%
Min Revenue beat(4)-4.27%
Max Revenue beat(4)6.12%
Revenue beat(8)7
Avg Revenue beat(8)1.8%
Revenue beat(12)11
Avg Revenue beat(12)3.37%
Revenue beat(16)15
Avg Revenue beat(16)4.63%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-11.18%
EPS NQ rev (3m)-15.59%
EPS NY rev (1m)3.35%
EPS NY rev (3m)2.13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.77%
Revenue NY rev (1m)0.68%
Revenue NY rev (3m)2.94%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.05 | ||
| Fwd PE | 16.09 | ||
| P/S | 4.9 | ||
| P/FCF | 14.13 | ||
| P/OCF | 13.57 | ||
| P/B | 2.87 | ||
| P/tB | 4.83 | ||
| EV/EBITDA | 9.9 |
EPS(TTM)0.93
EY3.99%
EPS(NY)1.45
Fwd EY6.22%
FCF(TTM)1.65
FCFY7.08%
OCF(TTM)1.72
OCFY7.37%
SpS4.75
BVpS8.11
TBVpS4.82
PEG (NY)0.45
PEG (5Y)1.76
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.12% | ||
| ROE | 21.38% | ||
| ROCE | 17.1% | ||
| ROIC | 13.92% | ||
| ROICexc | 29.06% | ||
| ROICexgc | 124.64% | ||
| OM | 32.18% | ||
| PM (TTM) | 36.44% | ||
| GM | 95.42% | ||
| FCFM | 34.69% |
ROA(3y)15.85%
ROA(5y)16.41%
ROE(3y)18.38%
ROE(5y)18.67%
ROIC(3y)15.19%
ROIC(5y)16.37%
ROICexc(3y)69.46%
ROICexc(5y)81.57%
ROICexgc(3y)103.42%
ROICexgc(5y)105.51%
ROCE(3y)18.66%
ROCE(5y)20.11%
ROICexcg growth 3Y22.47%
ROICexcg growth 5Y10.4%
ROICexc growth 3Y-22.82%
ROICexc growth 5Y-14.86%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score5
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 0.14 | ||
| Debt/EBITDA | 0.13 | ||
| Cap/Depr | 73.61% | ||
| Cap/Sales | 1.41% | ||
| Interest Coverage | 197.91 | ||
| Cash Conversion | 105.87% | ||
| Profit Quality | 95.19% | ||
| Current Ratio | 5.25 | ||
| Quick Ratio | 5.24 | ||
| Altman-Z | 9.12 |
F-Score5
WACC6.82%
ROIC/WACC2.04
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.37%
EPS 3Y13.04%
EPS 5Y14.25%
EPS Q2Q%-57.68%
EPS Next Y55.36%
EPS Next 2Y38.79%
EPS Next 3Y36.51%
EPS Next 5Y22.52%
Revenue 1Y (TTM)30.67%
Revenue growth 3Y36.75%
Revenue growth 5Y32.03%
Sales Q2Q%41.39%
Revenue Next Year17.69%
Revenue Next 2Y16.08%
Revenue Next 3Y19.84%
Revenue Next 5Y13.17%
EBIT growth 1Y30.18%
EBIT growth 3Y33.83%
EBIT growth 5Y21.83%
EBIT Next Year27.12%
EBIT Next 3Y26.62%
EBIT Next 5Y18.23%
FCF growth 1Y6.61%
FCF growth 3Y55.76%
FCF growth 5Y43.79%
OCF growth 1Y5.3%
OCF growth 3Y51.65%
OCF growth 5Y42.43%